Ann Dermatol.  2016 Jun;28(3):371-374. 10.5021/ad.2016.28.3.371.

CD30-Positive Anaplastic Lymphoma Kinase-Negative Systemic Anaplastic Large-Cell Lymphoma in a 9-Year-Old Boy

  • 1Department of Dermatology, Hanyang University College of Medicine, Seoul, Korea.


Anaplastic large-cell lymphoma (ALCL) is a CD30-positive T-cell/null-cell lymphoma that is clinically classified into either primary cutaneous ALCL or systemic ALCL (S-ALCL) sub-types. Because 90% of childhood S-ALCL cases are anaplastic lymphoma kinase (ALK)-positive, there is a lack of data on ALK-negative S-ALCL cases among pediatric patients. Herein, we report a rare case of ALK-negative S-ALCL in a 9-year-old Korean boy who initially presented with itchy erythematous maculopapules and an erosive nodule on the trunk area. We emphasize the need of high index of suspicion of an underlying malignant disease in the presence of refractory eczematous lesions.


Anaplastic lymphoma kinase; Anaplastic large-cell lymphoma; Eczema

MeSH Terms

Lymphoma, Large-Cell, Anaplastic*


  • Fig. 1 (A) Scattered erythematous maculopapules and an erosive nodule on the trunk (inset: close-up view). (B) Arrows indicate multiple hypermetabolic [18F] fluoro-2-deoxyglucose uptake observed on positron emission tomography.

  • Fig. 2 (A) A skin biopsy specimen from the erosive nodule showed epidermal erosion and diffuse dermal cellular infiltration (H&E, ×12.5). (B) The infiltration consisted of large atypical cells with eccentric nuclei admixed with inflammatory cells (H&E, ×200). Immunohistochemical staining of the specimen showed positivity for (C) CD30 with a membranous staining pattern on large cells (×100), as well as negativity for (D) anaplastic lymphoma kinase (×100).

  • Fig. 3 After chemotherapy, tiny papular lesions and a nodular erosive lesion were regressed with a subtle biopsy scar (inset: close-up view).


1. Sandlund JT, Pui CH, Roberts WM, Santana VM, Morris SW, Berard CW, et al. Clinicopathological features and treatment outcomes of children with large cell lymphoma and t(2;5)(p23;q35). Blood. 1994; 84:2467–2471.
2. Wright D, McKeever P, Carter R. Childhood non-Hodgkin lymphomas in the United Kingdom: findings from the UK children's cancer study group. J Clin Pathol. 1997; 50:128–134.
3. Lowe EJ, Gross TG. Anaplastic large cell lymphoma in children and adolescents. Pediatr Hematol Oncol. 2013; 30:509–519.
4. Stein H, Foss HD, Dürkop H, Marafioti T, Delsol G, Pulford K, et al. CD30(+) anaplastic large cell lymphoma: a review of histopathologic, genetic and clinical features. Blood. 2000; 96:3681–3695.
5. Hwang IG, Yoo KH, Lee SH, Park YH, Lim TK, Lee SC, et al. Clinicopathologic features and treatment outcomes in malignant lymphoma of pediatric and young adult patients in Korea: comparison of korean all-ages group and Western younger age group. Clin Lymphoma Myeloma. 2007; 7:580–586.
6. Burkhardt B, Zimmermann M, Oschlies I, Niggli F, Mann G, Parwaresch R, et al. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol. 2005; 131:39–49.
7. Kocabaş E, Türel Ermertcan A, Akinci S, Temiz P, Gündüz K. Primary cutaneous CD30-positive anaplastic large cell lymphoma in a 16-year-old girl. Int J Dermatol. 2012; 51:1353–1358.
8. Kim HS, Sim SJ, Kim DC, Kim JS, Song KH, Kim KH. A case of ALK-negative systemic anaplastic large cell lymphoma. Ann Dermatol. 2004; 16:125–131.
9. Oschlies I, Lisfeld J, Lamant L, Nakazawa A, d'Amore ES, Hansson U, et al. ALK-positive anaplastic large cell lymphoma limited to the skin: clinical, histopathological and molecular analysis of 6 pediatric cases. A report from the ALCL99 study. Haematologica. 2013; 98:50–56.
10. Ju E, Adigun C, Dunphy C, Gold S, Morrell DS. Anaplastic large cell lymphoma: an unusual presentation in a 7-year-old girl. Pediatr Dermatol. 2012; 29:498–503.
11. ten Berge RL, Oudejans JJ, Ossenkoppele GJ, Meijer CJ. ALK-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects--a review. J Pathol. 2003; 200:4–15.
12. Le Deley MC, Reiter A, Williams D, Delsol G, Oschlies I, McCarthy K, et al. Prognostic factors in childhood anaplastic large cell lymphoma: results of a large European intergroup study. Blood. 2008; 111:1560–1566.
13. Brugières L, Quartier P, Le Deley MC, Pacquement H, Perel Y, Bergeron C, et al. Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children--a report from the French Society of Pediatric Oncology. Ann Oncol. 2000; 11:53–58.
14. Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, et al. ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the international peripheral T-Cell lymphoma project. Blood. 2008; 111:5496–5504.
15. Wang YF, Yang YL, Gao ZF, Zhou CJ, Gregg X, Shi YF, et al. Clinical and laboratory characteristics of systemic anaplastic large cell lymphoma in Chinese patients. J Hematol Oncol. 2012; 5:38.
16. Mori T, Kiyokawa N, Shimada H, Miyauchi J, Fujimoto J. Anaplastic large cell lymphoma in Japanese children: retrospective analysis of 34 patients diagnosed at the National Research Institute for Child Health and Development. Br J Haematol. 2003; 121:94–96.
Full Text Links
  • AD
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2023 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: